oMARIgliptin once A week dpp-4 inhibitor post-marketinG surveillance on safety and Efficacy
Not Applicable
Recruiting
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000026134
- Lead Sponsor
- MSDK.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 3000
Inclusion Criteria
Not provided
Exclusion Criteria
Not applicable
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method [Safety] The incidence of side effects(Primary endpoint) [Efficacy] Overall impression on efficacy HbA1c change from baseline [Other] Compliance status Concomitant therapies
- Secondary Outcome Measures
Name Time Method